rBIO announced that it has completed all the required analytical characterizations of its insulin biosimilar, R-biolin. This positions the company to file for the 351(k) drug submission process — an abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference product.
Read MoreCureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.
Read MoreGero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.
Read MoreCyclica will apply its AI-enabled drug discovery platform to discover new therapeutic options with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.
Read MoreThe clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.
Read More